FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Immunic's Trailing 12-Month Free Cash Flow is $-71.16 Mil, and Market Cap is $113.68 Mil. Therefore, Immunic's FCF Yield % for today is -62.60%.
The historical rank and industry rank for Immunic's FCF Yield % or its related term are showing as below:
IMUX'
s FCF Yield % Range Over the Past 10 Years
Min: -161.39 Med: 0 Max: 0
Current: -62.6
IMUX's FCF Yield % is ranked worse than 78.09% of 1552
companies
in the Biotechnology industry
Industry Median: -14.81
vs IMUX: -62.60
The historical data trend for Immunic's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Immunic's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunic's FCF Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunic's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Immunic's FCF Yield % falls into.
Immunic FCF Yield % Calculation
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Immunic's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunic FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Immunic FCF Yield % Related Terms
Thank you for viewing the detailed overview of Immunic's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IMUX has been successfully added to your 